China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its potential best-in-class ENPP1 inhibitor, ISM5939, in solid tumors.
ISM5939: A Promising ENPP1 Inhibitor
ISM5939 targets ENPP1, an external nucleotide pyrophosphatase that plays a crucial role in regulating purine signaling, which impacts immune, cardiovascular, nervous system, tissue mineralization, and hematological functions. High expression levels of ENPP1 have been linked to tumor metastasis, immune escape, and poor prognosis across multiple cancer types. The development of ISM5939 is a significant step towards addressing these challenges in cancer treatment.
Preclinical Success and Therapeutic Potential
In preclinical trials, ISM5939 has shown a broad safety window and demonstrated therapeutic potential when used in combination with other drugs. This suggests that ISM5939 could offer a new treatment option for patients with solid tumors, potentially improving outcomes by targeting a key regulatory enzyme in cancer progression.-Fineline Info & Tech
